SACUBITRIL; VALSARTAN | A213728 | MACLEODS PHARMACEUTICALS LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
NOVARTIS PHARMACEUTICALS CORPORATION v. MACLEODS PHARMACEUTICALS LTD. et al 3 patentsANDA 213728sacubitril/valsartan | D.N.J. | 2019-10-25 | Terminated 2019-11-19 | — |
Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited et al 4 patentsANDA 213682, 213728, 213689sacubitril/valsartan | D. Del. | 2019-10-24 | Terminated 2025-07-17 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.5859
per ea
Lowest NADAC/Unit
$0.5306
per ea
Brand NDCs
0
Generic NDCs
6
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 33342057209SACUBITRIL-VALSARTAN 97-103 MG | $0.5859 | EA | Generic | — | 2026-06-17 |
| 33342057257SACUBITRIL-VALSARTAN 97-103 MG | $0.5859 | EA | Generic | — | 2026-06-17 |
| 33342057109SACUBITRIL-VALSARTAN 49-51 MG | $0.5485 | EA | Generic | — | 2026-06-17 |
| 33342057157SACUBITRIL-VALSARTAN 49-51 MG | $0.5485 | EA | Generic | — | 2026-06-17 |
| 33342057009SACUBITRIL-VALSARTAN 24-26 MG | $0.5306 | EA | Generic | — | 2026-06-17 |
| 33342057057SACUBITRIL-VALSARTAN 24-26 MG | $0.5306 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.